A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

AIM: We tested the hypothesis that dapagliflozin may regress left ventricular hypertrophy (LVH) in people with type 2 diabetes (T2D). METHODS AND RESULTS: We randomly assigned 66 people (mean age 67 ± 7 years, 38 males) with T2D, LVH, and controlled blood pressure (BP) to receive dapagliflozin 10 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Alexander J M, Gandy, Stephen, McCrimmon, Rory, Houston, John Graeme, Struthers, Allan D, Lang, Chim C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202417/
https://www.ncbi.nlm.nih.gov/pubmed/32578850
http://dx.doi.org/10.1093/eurheartj/ehaa419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202417/
https://www.ncbi.nlm.nih.gov/pubmed/32578850
http://dx.doi.org/10.1093/eurheartj/ehaa419

Ejemplares similares